2022 World Conference on Lung Cancer (ePosters)-EP08.02-115. A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

EP08.02-115. A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

Back to course

Pdf Summary

A retrospective, multicenter, observational study was conducted to evaluate the outcomes of lorlatinib treatment after alectinib in ALK-positive non-small cell lung cancer (NSCLC) patients in Japan. Alectinib is the most recommended first-line ALK tyrosine kinase inhibitor (TKI) according to Japanese treatment guidelines. After disease progression on alectinib, treatment options include lorlatinib, brigatinib, and ceritinib. Lorlatinib is a third-generation ALK TKI that has shown favorable efficacy in previous clinical trials.<br /><br />The study included 51 patients who received lorlatinib as second-line (2L) or third-line (3L) treatment. The median time to treatment failure (TTF) was 11.1 months for patients who received any line of lorlatinib treatment. Median TTF was 10.8 months for 2L lorlatinib and 11.5 months for 3L lorlatinib. Patients with brain metastases had a median TTF of 11.5 months, while patients without brain metastases had a median TTF of 9.9 months.<br /><br />The objective response rate (ORR) with lorlatinib was 35.7% for any-line treatment, 44.0% for 2L, and 23.5% for 3L. These results were consistent with the efficacy of lorlatinib observed in a previous phase 2 study. Overall, lorlatinib showed favorable clinical efficacy in patients with ALK-positive NSCLC.<br /><br />In conclusion, this real-world study demonstrated the characteristics, utilization, and clinical efficacy of lorlatinib in ALK-positive NSCLC patients after alectinib treatment. Median TTF and ORR were consistent with previous clinical trials, supporting the use of lorlatinib as a treatment option for patients who progress on alectinib.

Asset Subtitle

Motohiro Tamiya

Meta Tag

Speaker Motohiro Tamiya

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

lorlatinib treatment

alectinib

ALK-positive NSCLC

tyrosine kinase inhibitor

clinical trials

treatment failure

brain metastases

objective response rate

real-world study